Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO) has exciting news for those living with house dust mite (HDM) allergic rhinitis: the detailed results from their clinical trial with their Bentrio® nasal spray have been published in Clinical and Translational Allergy, one of the leading journals in the field of allergology.
Altamira is devoted to developing therapeutics that address important unmet medical needs, and this breakthrough study is a substantial step towards doing just that.
Thirty-seven Canadians suffering from perennial allergic rhinitis participated in a clinical trial to evaluate the effectiveness of Bentrio in reducing PAR symptoms. A double-blind crossover design was used, meaning patients were randomly assigned to receive either Bentrio in a single or double dose, a placebo, or no treatment prior to the controlled allergen exposure in a challenge chamber. Each exposure session was three hours long and administered over three consecutive days. The results of the trial may help inform future treatments for this widespread allergy.
Bentrio treatment was shown to be effective against an increase in nasal symptoms, as demonstrated by the Total Nasal Symptom Score (TNSS). After a single application of the treatment, the TNSS decreased by an impressive 1.1 points, with a 95% confidence interval between -1.87 and -0.28. This suggests that Bentrio treatment can provide protection from the symptoms for up to 3 hours!
Additionally, patient ratings of global tolerability found the treatment to be highly effective, with 86% rating it as good or very good. Thus, Bentrio treatment is an effective choice for relief against nasal symptoms.
Altamira Therapeutics’ founder, Chairman and CEO Thomas Meyer was thrilled with the positive results from the house dust mite challenge study as it further solidified the significant protective effects of Bentrio regardless of the type of inhaled allergen particles.
What’s more, Bentrio’s impact was shown to last for several hours, contributing to a 3.5-hour protective film on the nasal mucosa – a far cry from the brief effects of the current standard-of-care in drug-free allergic rhinitis management, saline nasal spray.
About House Dust Mite Allergies
Allergies triggered by dust mite (HDM) allergens are a serious global problem, affecting up to 130 million people worldwide. In the United States alone, they are the second most common source of allergies after plant-related allergens, affecting one in five individuals aged six and over.
Symptoms of an HDM allergy include sneezing, runny or stuffy noses, itching, coughing, difficulty breathing, and chest tightness or pain – which may be constant throughout the year, as compared to seasonal plant allergies such as hay fever. With such a widespread impact, it is clear that HDM allergies should not be taken lightly.
About Altamira Therapeutics
At Altamira (Nasdaq: CYTO), we are forging groundbreaking solutions to the world’s healthcare challenges. Our pioneering approach focuses upon developing RNA-based therapeutics through our OligoPhore™ and SemaPhore™ delivery platforms. We are currently investigating two potential treatments – AM-401 to battle KRAS-driven cancer and AM-411 for rheumatoid arthritis.
In addition, our versatile delivery mechanism can potentially be used with mRNA, as well as other forms of RNA therapy. We are hoping to expand our horizon by licensing our legacy assets – Bentrio® OTC nasal spray, AM-125 nasal spray (for vertigo) after Phase 2, and Keyzilen® and Sonsuvi® (for tinnitus and hearing loss) in Phase 3 – to pharmaceutical or biotech companies. Founded in 2003, Altamira is based in Hamilton, Bermuda and has its main operations in Basel, Switzerland. Join us as we work to revolutionise the world of healthcare!